TREM2 Modulation as Anti-Inflammatory Approach for the Treatment of AD – Is There a Space Beside Anti-Amyloid Beta & Tau Agents?
Time: 3:30 pm
day: Conference Day One
Details:
- Development of anti-amyloid antibodies were highly dependent on biomarker development and the correlation with therapeutic efficacy has been crucial
- The link with neuroinflammation, AD pathology and therapeutic efficacy is yet to be established
- Clinical assessment of agents acting at TREM2 and linking their mechanistic efficacy with the impact on AD pathology will be key to successfully develop these agents